Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ADAG, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Amezalpat (TPST-1120) | Advanced Liver Cancers | Phase 1/2 · NCT04524871 | Active not recruiting |
| Tobemstomig | Advanced Liver Cancers | Phase 1/2 · NCT04524871 | Active not recruiting |
| Tiragolumab | Advanced Liver Cancers | Phase 1/2 · NCT04524871 | Active not recruiting |
| Pembrolizumab & ADG106 (Phase Ib) | Advanced Solid Tumor | Phase 1/2 · NCT05491083 | Recruiting |
| PD-1 antibody injection | Solid Tumor | Phase 1/2 · NCT04775680 | Terminated |
| Imdatifan (NKT2152) | Advanced Liver Cancers | Phase 1/2 · NCT04524871 | Active not recruiting |
| Anti-CD137 Agonistic Monoclonal Antibody | HER2-negative Breast Cancer | Phase 1/2 · NCT05275777 | Active not recruiting |
| Anti-LILRB2 Monoclonal Antibody IO-108 | Advanced Liver Cancers | Phase 1/2 · NCT04524871 | Active not recruiting |
| Doxorubicin | HER2-negative Breast Cancer | Phase 1/2 · NCT05275777 | Active not recruiting |
| Muzastotug (ADG126) | Advanced/Metastatic Solid Tumors | Phase 1/2 · NCT04645069 | Completed |
| anti PD1 drug | Advanced/Metastatic Solid Tumors | Phase 1 · NCT04501276 | Completed |
| Anti-CD137 Agonistic Monoclonal Antibody | Advanced/Metastatic Solid Tumors | Phase 1 · NCT05614258 | Active not recruiting |
| Firastotug (ADG116) | Advanced/Metastatic Solid Tumors | Phase 1 · NCT04501276 | Completed |
Also used in these trials (approved or third-party drugs, not ADAG's own candidates): Nivolumab, Tocilizumab, Pembrolizumab, Paclitaxel, Cyclophosphamide, Bevacizumab, Atezolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ADAG holds $127.9M in cash and short-term investments and burns about $4.8M/quarter from operations, an estimated runway of 79.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 15 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ADAG files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| HAN 2020 Irrevocable Trust | 5%+ holder (13D) | 9,390,439 | 15.85% | 2026-06-05 |
| JANUS HENDERSON GROUP PLC | Institution (13G, 5%+) | 6,666,666 | 11.26% | 2026-04-30 |
| Smith Vincent C | 5%+ holder (13G) | 5,095,351 | 8.60% | 2025-12-31 |
| Chernett Jorey | 5%+ holder (13G) | 2,389,060 | 4.03% | 2026-03-16 |
| Mickael Yannick Chane-Du Chief Strategy Officer |
Insider | 467,525 | 0.79% | 2026-03-18 |
| Qinghai Zhao Chief Manufacturing Officer |
Insider | 130,214 | 0.22% | 2026-03-18 |
| Peter Luo Chief Executive Officer, Director |
Insider | 88,535 | 0.15% | 2026-09-16 |
| Ulf Grawunder Director · +85,000 options |
Insider | 25,000 | 0.04% | 2026-03-17 |
| Man Kin Tam Chief Financial Officer, Director |
Insider | 12,000 | 0.02% | 2026-09-23 |
| Chunfang Gu Executive Director of Finance |
Insider | 5,775 | 0.01% | 2026-09-30 |
| Ling Zhou ED of Human Resources |
Insider | 2,969 | 0.01% | 2026-03-18 |
| Cuong V Do Director · +110,000 options |
Insider | 2,000 | 0.00% | 2026-08-14 |
Share count 59,231,993 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADAG and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →